BRIDGEWATER, N.J.–(BUSINESS WIRE<\/a>)– \nCREXONT, which is indicated for the treatment of Parkinson\u2019s disease (PD), is a novel formulation of CD\/LD that combines both IR granules and extended-release pellets. This innovative design allows for rapid onset, while leveraging a sustained-release polymer for slow LD release, potentially enabling longer LD absorption in the gut.\n<\/p>\n \nThe new analysis showed that patients on CREXONT, compared to IR CD\/LD, also experienced statistically significant improvements across all PDSS-2 subdomains, including reduced disturbed sleep (-1.07, p<\/i><0.0001), improved nighttime motor symptoms (\u20110.62, p<\/i><0.0059) and PD symptoms at night (-0.65, p<\/i><0.0017). Full results will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting on April 9 at 8 a.m. PST.\n<\/p>\n \n“I\u2019ve seen firsthand how common sleep disturbances are among patients with Parkinson’s disease and the profound impact they have on daily life. Improving sleep quality is not only essential for effective disease management, but also critical for enhancing overall patient care and well-being,” said Dr. Robert Hauser, a study author and Professor of Neurology at the Parkinson\u2019s Disease and Movement Disorders Center, University of South Florida. “The new Phase 3 data analysis shows CREXONT\u2019s ability to significantly improve sleep, in addition to its effects on daytime PD symptoms, making it a valuable treatment option for patients dealing with the challenges of this debilitating condition.\u201d\n<\/p>\n \nA separate analysis of Hauser diary entries, which is a commonly used PD symptom tracking tool, from patients who completed the RISE-PD study will also be presented at AAN. Treatment with CREXONT compared to IR CD\/LD resulted in significant increases in the number of patients who reported waking up in an \u201cOn\u201d state and patients who never recorded being in an \u201cOff\u201d state upon awakening. Furthermore, the percentage of patients who never recorded \u201cOn\u201d upon awakening decreased with CREXONT vs. IR CD\/LD.\n<\/p>\n \n“It\u2019s exciting to see the expanding body of research supporting CREXONT and its positive impact on patients. As we continue to explore the full benefits of CREXONT, we are optimistic that increased \u2018On\u2019 time throughout the day with fewer doses \u2013 and as now demonstrated, enhanced sleep quality \u2013 can help improve overall quality of life for more PD patients,\u201d said Joe Renda, Senior Vice President, Chief Commercial Officer \u2013 Specialty at Amneal Pharmaceuticals. \u201cThe rising prevalence of Parkinson\u2019s disease underscores the need for continued innovation, and Amneal remains dedicated to providing solutions that improve PD patient outcomes.\u201d\n<\/p>\n \nAmneal has initiated a Phase 4 clinical trial, ELEVATE-PD, to evaluate the real-world efficacy and safety of CREXONT in patients with PD.\n<\/p>\n \nThe most common adverse reactions with CREXONT (incidence \u22653% and greater than IR CD\/LD) are nausea and anxiety. See Important Safety Information below.\n<\/p>\n About the RISE-PD Phase 3 Trial<\/b><\/p>\n \nThe multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group RISE-PD trial evaluated the efficacy and safety of CREXONT compared with IR CD\/LD in the treatment of patients with PD who have motor fluctuations. The primary endpoint of the trial assessed the change from baseline in \u201cOn\u201d time in hours per day at the end of the double-blind treatment period (Week 20 or early termination). Secondary endpoints assessed the change from baseline in \u201cOff\u201d time in hours per day, proportion of patients who were either \u201cmuch improved\u201d or \u201cvery much improved\u201d in Patients’ Global Impression of Change (PGI-C) scores, change from baseline in the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III score, and the change from baseline in sum of MDS-UPDRS Parts II and III scores. The study included 506 patients who had received a PD diagnosis at age 40 or older.\n<\/p>\n About CREXONT<\/b>\u00ae\n<\/p>\n \nCREXONT is an innovative formulation consisting of immediate-release granules with carbidopa and levodopa for rapid onset of action, and extended-release pellets with levodopa for long-lasting efficacy. CREXONT formulation and dosage strengths are different from RYTARY\u00ae (carbidopa and levodopa) extended-release capsules approved by the U.S. FDA in 2015. Learn more about CREXONT at crexont.com<\/a>.\n<\/p>\n INDICATION<\/b><\/p>\n \nCREXONT (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson\u2019s disease, Parkinson\u2019s disease caused by infection or inflammation of the brain, or Parkinson\u2019s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.\n<\/p>\n IMPORTANT SAFETY INFORMATION<\/b><\/p>\n Tell your healthcare provider if you:<\/b><\/p>\n To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals, LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or <\/b>www.fda.gov\/medwatch<\/b><\/a>.<\/b><\/p>\n \nPlease read the full Prescribing Information<\/a>. For more information talk to your healthcare provider.\n<\/p>\n About Parkinson\u2019s Disease<\/b><\/p>\n \nParkinson\u2019s disease (PD) has become the fastest growing neurological disorder worldwide, with approximately 1 million people diagnosed in the U.S.2,3<\/sup> It is a progressive disorder of the central nervous system (CNS) that affects dopamine-producing neurons in the brain that affect movement. PD is characterized by slowness of movement, stiffness, resting tremor and impaired balance.4<\/sup> While PD is not considered a fatal disease, it is associated with significant morbidity and disability.5<\/sup> The average age at diagnosis for people with PD is 60; as people live longer, the number of people living with PD is predicted to grow significantly over the coming decades.2,6<\/sup><\/p>\n About Amneal<\/b><\/p>\n \nAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com<\/a> and follow us on LinkedIn<\/a>.\n<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nCertain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management\u2019s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as \u201cplans,\u201d \u201cexpects,\u201d \u201cwill,\u201d \u201canticipates,\u201d \u201cestimates,\u201d and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company\u2019s filings with the Securities and Exchange Commission, including under Item 1A, \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.\n<\/p>\n
\nAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (\u201cAmneal\u201d or the \u201cCompany\u201d), a global biopharmaceutical company, today announced a new analysis of the pivotal RISE-PD Phase 3 study showed that patients who successfully converted to CREXONT from immediate release (IR) carbidopa\/levodopa (CD\/LD) experienced statistically significant improvements in sleep quality. These improvements were measured by their Parkinson\u2019s Disease Sleep Scale-2 (PDSS-2) total scores, showing a mean difference of -2.35 (p<<\/i>0.0001).\n<\/p>\n\n
\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250407981059\/en\/1956686\/3\/AMRX_Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n